Ye Weiguo sold $219K of GYRE
Ye Weiguo (Chief Operating Officer) sold 34,976 shares of GYRE THERAPEUTICS, INC. (GYRE) at an average of $6.25 ($6.13–$6.40, $0.22M total) across 2 trades over 2026-06-04 to 2026-06-05.
How this was made
The 30-second read
Why it matters
The newest fact is the COO’s open-market sale amount, share count, and post-transaction holdings; it may modestly affect sentiment but does not change company fundamentals on its own.
Market read
A company-specific insider sale was newly disclosed; it is more relevant for sentiment/positioning than for forecasting clinical or regulatory outcomes.
What to watch
The absence of a stated 10b5-1 plan increases interpretive noise; traders should compare with prior insider patterns and any concurrent institutional/clinical catalysts.
Background
The article is an SEC Form 4 insider transaction disclosure for GYRE Therapeutics, Inc.
Ticker impact
SEC Form 4 shows COO Ye Weiguo sold 34,976 shares of GYRE for ~$218.6K in open-market trades (6/4–6/5).
Likely limited/short-lived impact; watch for follow-through selling or other insider activity rather than a directional repricing.
The filing is primary-source and company-specific, but the transaction is small relative to typical biotech market caps and provides no new operational/clinical/regulatory information.
Market effects
Insider-sale disclosures can slightly influence sentiment across small-cap biotech, but this filing alone does not imply sector-wide fundamentals.
None indicated; US-listed issuer filing only.
None indicated; no cross-border deal/regulatory event mentioned.
Counterpoint
Insider sales can be planned for liquidity/tax and may not reflect negative expectations—especially with multi-trade execution across two days.
Key entities
- issuerGYRE Therapeutics, Inc.
US-listed biotech issuer; subject of the Form 4 insider sale disclosure.
- insiderYe Weiguo
Chief Operating Officer who sold 34,976 shares in open-market transactions.